SX-682
Phase 1 Trial of SX-682, a CXCR 1/2 Inhibitor, in Combination With Standard of Care Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1
- Enrollment
- 15 patients (estimated)
- Sponsors
- Roswell Park Cancer Institute
- Tags
- CXCR1 Inhibitor, CXCR2 Inhibitor, Quadruplet Therapy
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 2014
- NCT Identifier
- NCT06622005
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.